NEOADAURA is a randomized, controlled, phase III trial that randomized 351 patients with resectable stage II-IIIB non-small-cell lung cancer (NSCLC; exon 19 del or exon 21 point mutations) to ...
Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling ...
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback